Edwards Lifesciences Corporation
EW
$76.04
$0.911.21%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.17B | 4.16B | 1.47B | 1.41B | 1.40B |
| Total Depreciation and Amortization | 155.20M | 149.30M | 151.70M | 148.20M | 144.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.53B | -3.49B | -50.50M | -115.50M | -125.20M |
| Change in Net Operating Assets | -259.30M | -12.30M | -708.10M | -918.30M | -526.30M |
| Cash from Operations | 542.30M | 806.40M | 866.10M | 528.20M | 895.80M |
| Capital Expenditure | -252.40M | -290.90M | -294.30M | -256.80M | -253.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.06B | -717.60M | 46.00M | 46.00M | -95.20M |
| Divestitures | 3.93B | 3.93B | -- | -- | -- |
| Other Investing Activities | -300.30M | -15.20M | 539.30M | 447.20M | 522.00M |
| Cash from Investing | 2.31B | 2.90B | 291.00M | 236.40M | 173.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 179.50M | 184.10M | 183.60M | 190.10M | 169.90M |
| Repurchase of Common Stock | -1.16B | -1.61B | -781.10M | -630.50M | -879.60M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.10M | -1.20M | 6.10M | -2.30M | -1.30M |
| Cash from Financing | -983.00M | -1.42B | -591.40M | -442.70M | -711.00M |
| Foreign Exchange rate Adjustments | 38.60M | -15.80M | 44.90M | 30.70M | 16.80M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.91B | 2.27B | 610.60M | 352.60M | 375.40M |